British Health Minister Sajid Javid has revealed the government’s autumn-winter plan to deal with the pandemic crisis, which includes a number of measures to prevent the need for further lockdowns.
His comments come shortly after UK officials gave the green light to offer a booster dose of the COVID-19 vaccine to those at risk and anyone over 50 six months after their second dose.
The UK Joint Committee on Immunization and Immunization has recommended a booster vaccination with a vaccine from Pfizer Inc (NYSE: PFE) – BioNTech SE (NASDAQ: BNTX) or half a dose of Moderna Company (NASDAQ: mRNA).
Should investors sell now? Or is it worth it Join Pfizer?
The National Health Service is expected to start doing so next week. Separately, all children aged 12 to 15 years in England will be offered a dose of the vaccine from Pfizer-BioNTech.
CNBC reports that Prime Minister Boris Johnson will provide more information on the country’s fall-winter Covid plan at a press conference in Downing Street this afternoon.
The majority of younger adults will not receive their second dose of the COVID-19 vaccine until late summer or early fall. The benefit of booster vaccination for this group will be evaluated later.
Buy, sell or buy BioNTech?
How will BioNTech evolve now? Is your money safe in this stock? Answers to these questions and why you should act now can be found in the current analysis of BioNTech stocks.